首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

2103098

全球注意力不足過動症（ADHD）新興療法報告：2026年第二季度

Global Attention Deficit Hyperactivity Disorder (ADHD) Emerging Therapies Report, 2026 (Q2 Update)

出版日期: 2026年07月11日 | 出版商:

Knowledge Sourcing Intelligence | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

全球新興注意力不足/過動症 (ADHD) 療法市場預計在預測期內將以 10.4% 的複合年成長率成長，從 2026 年的 9.1 億美元成長到 2035 年的 22.1 億美元。

隨著製藥公司、生技公司、學術機構和神經科學研究機構加速開發新一代療法，全球注意力不足過動症 (ADHD) 新興療法市場正大幅擴張。本分析全面深入探討了在臨床實驗藥物、新型作用機制、臨床開發進展、研發管線成熟度、許可活動、監管里程碑和商業化機會。儘管興奮劑已被廣泛應用，但仍存在未被滿足的臨床需求，促使研發人員日益關注能夠提高療效、增強安全性、延長作用持續時間並降低濫用風險的創新療法。

目前，過動症的治療仍主要依賴興奮劑，非興奮劑療法則相對較少。雖然這些療法對許多患者有效，但人們對副作用、心血管安全性、食慾抑制、睡眠障礙、治療順從性和藥物濫用等問題的擔憂，持續推動替代療法的研究。新的療法包括選擇性神經傳導物質調變器、新型非興奮劑化合物、長效製劑、精準醫療方法、數位療法、神經刺激技術以及旨在滿足兒童、青少年和成人患者多樣化需求的聯合療法策略。

神經科學、基因組學、人工智慧和生物標記研究的進步也為治療前景帶來了益處。這些技術正在改善標靶識別、患者分層、臨床試驗設計和治療反應預測。數位健康解決方案、穿戴式監測設備、電子病患報告結局（PRO）和分散式臨床試驗進一步提高了治療研發的效率，同時產生高品質的真實世界數據，為監管和商業性決策提供支援。

各年齡層對注意力不足過動症（ADHD）的認知度不斷提高，診斷率持續上升，醫療保健支出不斷成長，以及對中樞神經系統研究投入的增加，都持續推動著新興療法在全球範圍內的發展。製藥公司、生技創新者、研究機構和技術供應商之間的策略合作，正在加速藥物研發進程，並為差異化療法創造新的機會。隨著多個前景可觀的候選藥物進入臨床開發階段，預計在預測期內，新興療法將重塑ADHD治療的未來。

市場促進因素

對新型治療方案的需求日益成長

與傳統興奮劑類藥物相關的限制不斷催生了對創新療法的需求，這些療法能夠提高安全性、降低濫用風險並提高患者遵守用藥。

開發人員正在積極進行非興奮劑化合物、新型藥理標靶和個人化治療方法的研究，以滿足尚未滿足的臨床需求。

非刺激性開發範圍擴大

人們對非興奮劑療法的興趣日益濃厚，這加速了選擇性神經傳導物質調變器和替代作用機制的研究。

這些治療方法旨在有效控制症狀，同時最大限度地減少與興奮劑相關的常見副作用。

數位和基於設備的療法的進展

數位療法、認知訓練平台、穿戴式科技和神經刺激設備正在成為補充或替代治療方案。

這些創新技術提供個人化的治療方案，同時拓展了治療選擇，突破了傳統藥物療法的限制。

加大神經科學研究的投資

各國政府、製藥公司、創業投資和學術機構都在不斷增加對神經發育障礙研究的投入。

科研經費的增加正在加速標靶發現、轉化醫學以及有前景的候選藥物的臨床開發方面的進展。

精準醫學簡介

遺傳學、生物標記和人工智慧的進步正在為多動症的個人化治療策略提供支援。

精準醫療能夠提高病患選擇的準確性，最佳化治療效果，並提高臨床開發計畫的效率。

市場限制因素

臨床開發週期越來越長。

需要進行廣泛的臨床評估，以證明新的 ADHD 療法的長期療效、安全性和耐受性。

漫長的研發週期可能會延遲監管部門的批准和商業化進程。

高昂的研發成本

藥物發現研究、多中心臨床試驗、監管申報和生產流程最佳化都需要大量的資金投入。

小規模的生物技術公司通常依靠許可協議和戰略合作夥伴關係來推進有前景的候選藥物的開發。

監管和安全要求

新的 ADHD 藥物必須符合嚴格的監管標準，包括療效、濫用風險、心血管安全性和長期臨床結果。

這些要求增加了開發的複雜性和商業化的風險。

The global attention deficit hyperactivity disorder (ADHD) emerging therapies market is witnessing significant expansion as pharmaceutical companies, biotechnology firms, academic institutions, and neuroscience research organizations accelerate the development of next-generation treatment options. Emerging therapies analysis provides comprehensive insights into investigational drugs, novel mechanisms of action, clinical development progress, pipeline maturity, licensing activities, regulatory milestones, and commercialization opportunities. As unmet clinical needs persist despite the widespread use of stimulant medications, developers are increasingly focusing on innovative therapies that offer improved efficacy, enhanced safety, longer duration of action, and reduced abuse potential.

Current ADHD treatment continues to rely primarily on stimulant medications and a limited number of non-stimulant therapies. Although these treatments are effective for many patients, concerns related to adverse effects, cardiovascular safety, appetite suppression, sleep disturbances, treatment adherence, and misuse continue to drive research into alternative therapeutic approaches. Emerging therapies include selective neurotransmitter modulators, novel non-stimulant compounds, long-acting formulations, precision medicine approaches, digital therapeutics, neurostimulation technologies, and combination treatment strategies designed to address the diverse needs of pediatric, adolescent, and adult patients.

The therapeutic landscape is also benefiting from advances in neuroscience, genomics, artificial intelligence, and biomarker research. These technologies are improving target identification, patient stratification, clinical trial design, and prediction of treatment response. Digital health solutions, wearable monitoring devices, electronic patient-reported outcomes, and decentralized clinical trials are further enhancing the efficiency of therapeutic development while generating high-quality real-world evidence to support regulatory and commercial decision-making.

Growing awareness of ADHD across all age groups, increasing diagnosis rates, expanding healthcare expenditure, and rising investment in central nervous system research continue to strengthen the global emerging therapies landscape. Strategic collaborations between pharmaceutical companies, biotechnology innovators, research institutions, and technology providers are accelerating development timelines while creating new opportunities for differentiated therapies. As several promising candidates advance through clinical development, emerging therapies are expected to reshape the future ADHD treatment landscape during the forecast period.

Market Drivers

Increasing Demand for Novel Therapeutic Options

Limitations associated with conventional stimulant medications continue to create demand for innovative therapies with improved safety, lower abuse potential, and enhanced patient adherence.

Developers are actively investigating non-stimulant compounds, novel pharmacological targets, and personalized treatment approaches capable of addressing unmet clinical needs.

Expansion of Non-Stimulant Drug Development

The growing interest in non-stimulant therapies has accelerated research into selective neurotransmitter modulators and alternative mechanisms of action.

These therapies aim to provide effective symptom control while minimizing adverse effects commonly associated with stimulant medications.

Advances in Digital and Device-Based Therapies

Digital therapeutics, cognitive training platforms, wearable technologies, and neurostimulation devices are emerging as complementary or alternative treatment options.

These innovations provide individualized treatment approaches while expanding therapeutic options beyond conventional pharmacological interventions.

Growing Investment in Neuroscience Research

Governments, pharmaceutical companies, venture capital firms, and academic institutions continue to increase investment in neurodevelopmental disorder research.

Rising research funding is accelerating target discovery, translational medicine, and advancement of promising pipeline candidates through clinical development.

Adoption of Precision Medicine

Advances in genetics, biomarkers, and artificial intelligence are supporting personalized ADHD treatment strategies.

Precision medicine enables improved patient selection, optimized therapeutic response, and more efficient clinical development programs.

Market Restraints

Lengthy Clinical Development Timelines

Emerging ADHD therapies require extensive clinical evaluation to demonstrate long-term efficacy, safety, and tolerability.

Lengthy development programs may delay regulatory approval and commercialization.

High Research and Development Costs

Discovery research, multicenter clinical trials, regulatory submissions, and manufacturing optimization require substantial financial investment.

Smaller biotechnology companies often rely on licensing agreements or strategic partnerships to advance promising candidates.

Regulatory and Safety Requirements

Novel ADHD therapies must satisfy rigorous regulatory standards regarding efficacy, abuse liability, cardiovascular safety, and long-term clinical outcomes.

These requirements increase development complexity and commercialization risk.

Technology and Segment Insights

By Development Phase

Phase II clinical trials represent a substantial portion of the emerging therapy pipeline as developers evaluate optimal dosing, efficacy, pharmacokinetics, and safety.

Phase III programs continue to expand as advanced candidates progress toward regulatory submission, while preclinical and Phase I research remains active through continuous introduction of innovative therapeutic mechanisms.

By Therapy Type

Small-molecule therapies continue to dominate the emerging pipeline because of established manufacturing processes and favorable pharmacological characteristics.

Non-stimulant medications represent one of the fastest-growing segments as developers seek alternatives with improved tolerability and lower abuse potential.

Digital therapeutics, neurostimulation devices, and combination therapies are also expanding rapidly as complementary treatment options for ADHD management.

By Mechanism of Action

Emerging therapies increasingly target multiple neurological pathways beyond traditional dopaminergic and noradrenergic systems.

Developers are evaluating selective receptor modulators, innovative neurotransmitter targets, and precision medicine approaches designed to improve therapeutic outcomes while minimizing adverse effects.

By End User

Pharmaceutical companies remain the largest participants in emerging therapy development due to sustained investment in drug discovery, clinical research, and commercialization.

Biotechnology companies continue to expand their presence through development of first-in-class therapies and innovative technology platforms.

Academic institutions, contract research organizations, and neuroscience research centers also contribute significantly through early-stage discovery, translational research, and collaborative clinical programs.

Regional Insights

North America dominates the global ADHD emerging therapies market due to its advanced pharmaceutical industry, robust biotechnology ecosystem, strong neuroscience research capabilities, and supportive regulatory environment. The United States remains the leading center for ADHD therapeutic innovation, hosting numerous investigational programs and strategic collaborations.

Europe represents another important market supported by collaborative academic research, established pharmaceutical companies, and increasing investment in neurodevelopmental disorders. Countries including Germany, the United Kingdom, France, Italy, and Spain continue to participate actively in multinational clinical development programs.

Asia Pacific is expected to record the fastest growth during the forecast period. Expanding healthcare infrastructure, increasing pharmaceutical research investment, improving regulatory pathways, and growing awareness of ADHD are strengthening therapeutic development across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa are gradually expanding participation in ADHD research through healthcare modernization, greater involvement in multinational clinical trials, and stronger collaboration with global pharmaceutical organizations.

Competitive and Strategic Outlook

The global ADHD emerging therapies market is characterized by active participation from multinational pharmaceutical companies, biotechnology innovators, academic research institutions, and specialty neuroscience developers. Competition increasingly focuses on developing differentiated therapies that offer improved efficacy, enhanced safety, longer treatment duration, and reduced abuse potential.

Organizations are investing in artificial intelligence, biomarker discovery, precision medicine, digital therapeutics, and advanced drug delivery technologies to strengthen pipeline competitiveness. Strategic licensing agreements, research collaborations, mergers, acquisitions, and co-development partnerships continue to accelerate clinical development while reducing research risk.

Future competition is expected to focus on first-in-class mechanisms of action, personalized treatment strategies, long-acting formulations, digital health integration, and innovative therapeutic platforms capable of addressing the evolving needs of pediatric and adult ADHD patients.

Conclusion

The global ADHD emerging therapies market is expected to experience robust growth as innovation continues to transform the treatment landscape for attention deficit hyperactivity disorder. Rising diagnosis rates, expanding investment in neuroscience research, increasing development of non-stimulant therapies, technological advances in digital health, and adoption of precision medicine are expected to drive sustained market expansion. Although lengthy clinical development timelines, regulatory complexity, and high research costs remain important challenges, continued scientific innovation and strategic collaboration are expected to accelerate the introduction of safer, more effective, and more personalized ADHD therapies.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Emerging Therapy Landscape Overview
1.4 Commercial Opportunity Assessment
1.5 Key Growth Drivers and Challenges
1.6 Future Outlook for ADHD Therapeutics

2. Disease & Epidemiology Analysis

2.1 Overview of Attention Deficit Hyperactivity Disorder (ADHD)
- 2.1.1 Definition and Clinical Characteristics
- 2.1.2 Disease Burden and Unmet Needs
- 2.1.3 Etiology and Risk Factors
- 2.1.4 Neurobiological Basis of ADHD
2.2 Disease Classification
- 2.2.1 Predominantly Inattentive Presentation
- 2.2.2 Predominantly Hyperactive-Impulsive Presentation
- 2.2.3 Combined Presentation
2.3 Signs and Symptoms
2.4 Diagnosis and Screening Guidelines
- 2.4.1 Diagnostic Criteria
- 2.4.2 Rating Scales and Assessment Tools
2.5 Epidemiology Analysis
- 2.5.1 Prevalence by Age Group
- 2.5.2 Prevalence by Gender
- 2.5.3 Diagnosed vs Undiagnosed Population
- 2.5.4 Epidemiological Trends and Forecast
2.6 Comorbidities Associated with ADHD
- 2.6.1 Anxiety Disorders
- 2.6.2 Depression
- 2.6.3 Autism Spectrum Disorder
- 2.6.4 Learning Disabilities
- 2.6.5 Sleep Disorders

3. Market Dynamics

3.1 Market Overview
3.2 Market Drivers
- 3.2.1 Increasing ADHD Diagnosis Rates
- 3.2.2 Growing Awareness and Early Screening
- 3.2.3 Expanding Adult ADHD Treatment Market
- 3.2.4 Advancements in Novel Therapeutic Modalities
3.3 Market Restraints
- 3.3.1 Safety Concerns Related to Stimulants
- 3.3.2 Drug Abuse and Dependence Risks
- 3.3.3 Regulatory Challenges
3.4 Market Opportunities
- 3.4.1 Non-Stimulant Drug Development
- 3.4.2 Digital Therapeutics and Combination Approaches
- 3.4.3 Precision Medicine Opportunities
3.5 Porter's Five Forces Analysis
3.6 PESTLE Analysis
3.7 Value Chain Analysis

4. Commercial & Market Access

4.1 Commercial Landscape Overview
4.2 Pricing Analysis
4.3 Reimbursement Landscape
- 4.3.1 Public Reimbursement
- 4.3.2 Private Insurance Coverage
4.4 Market Access Challenges
4.5 Generic Competition and Patent Expiry Analysis
4.6 Patient Assistance Programs
4.7 Distribution and Supply Chain Assessment

5. Innovation & Pipeline Landscape

5.1 Innovation Trends in ADHD Therapeutics
5.2 Emerging Treatment Modalities
- 5.2.1 Novel Stimulants
- 5.2.2 Non-Stimulant Therapies
- 5.2.3 Extended-Release Formulations
- 5.2.4 Transdermal Drug Delivery Systems
- 5.2.5 Digital Therapeutics
5.3 Pipeline Analysis by Clinical Stage
- 5.3.1 Discovery and Preclinical Stage
- 5.3.2 Phase I Pipeline
- 5.3.3 Phase II Pipeline
- 5.3.4 Phase III Pipeline
5.4 Pipeline Analysis by Mechanism of Action
- 5.4.1 Dopamine and Norepinephrine Reuptake Inhibitors
- 5.4.2 Triple Reuptake Inhibitors
- 5.4.3 Selective Norepinephrine Reuptake Inhibitors
- 5.4.4 Monoamine Modulators
- 5.4.5 Novel CNS Targets
5.5 Pipeline Analysis by Modality
- 5.5.1 Small Molecules
- 5.5.2 Drug Delivery Technologies
- 5.5.3 Digital Therapeutics
5.6 Clinical Trial Landscape
5.7 Licensing, Collaborations, and Strategic Partnerships

6. Treatment Landscape

6.1 Current Treatment Paradigm
6.2 Pharmacological Treatment Overview
6.3 Stimulant Therapies
- 6.3.1 Amphetamine-Based Therapies
- 6.3.2 Methylphenidate-Based Therapies
6.4 Non-Stimulant Therapies
- 6.4.1 Atomoxetine-Based Therapies
- 6.4.2 Viloxazine-Based Therapies
- 6.4.3 Alpha-2 Adrenergic Agonists
6.5 Approved ADHD Drugs Analysis
- 6.5.1 Brand and Generic Overview
- 6.5.2 Safety and Efficacy Comparison
- 6.5.3 Dosage Forms and Administration
6.6 Non-Pharmacological Therapies
- 6.6.1 Behavioral Therapy
- 6.6.2 Cognitive Behavioral Therapy
- 6.6.3 Parent Training Programs
- 6.6.4 Educational Interventions
6.7 Treatment Algorithm and Clinical Guidelines

7. Global Attention Deficit Hyperactivity Disorder (ADHD) Emerging Therapies Report Size & Forecast

7.1 Global Market Overview
7.2 Historical Market Size Analysis
7.3 Forecast Market Size Analysis
7.4 Market Forecast by Therapy Type
7.5 Market Forecast by Route of Administration
7.6 Market Forecast by Distribution Channel
7.7 Market Forecast by End User
7.8 Emerging Therapies Market Opportunity Assessment

8. Global Attention Deficit Hyperactivity Disorder (ADHD) Emerging Therapies Report Segmentation

8.1 By Drug Class
- 8.1.1 Stimulants
  - 8.1.1.1 Amphetamine-Based Drugs
  - 8.1.1.2 Methylphenidate-Based Drugs
- 8.1.2 Non-Stimulants
  - 8.1.2.1 Selective Norepinephrine Reuptake Inhibitors
  - 8.1.2.2 Alpha-2 Adrenergic Agonists
8.2 By Age Group
- 8.2.1 Pediatric & Adolescent ADHD
- 8.2.2 Adult ADHD
8.3 By Route of Administration
- 8.3.1 Oral
- 8.3.2 Transdermal
8.4 By End User
- 8.4.1 Hospitals
- 8.4.2 Specialty Clinics
- 8.4.3 Homecare Settings
8.5 By Distribution Channel
- 8.5.1 Hospital Pharmacies
- 8.5.2 Retail Pharmacies
- 8.5.3 Online Pharmacies

9. Geographical Analysis

9.1 North America
- 9.1.1 Market Size and Forecast
- 9.1.2 Demand Drivers
- 9.1.3 Regional Regulatory Overview
- 9.1.4 Competitive Intensity
9.2 Europe
- 9.2.1 Market Size and Forecast
- 9.2.2 Demand Drivers
- 9.2.3 Regional Regulatory Overview
- 9.2.4 Competitive Intensity
9.3 Asia-Pacific
- 9.3.1 Market Size and Forecast
- 9.3.2 Demand Drivers
- 9.3.3 Regional Regulatory Overview
- 9.3.4 Competitive Intensity
9.4 Latin America
- 9.4.1 Market Size and Forecast
- 9.4.2 Demand Drivers
- 9.4.3 Regional Regulatory Overview
- 9.4.4 Competitive Intensity
9.5 Middle East & Africa
- 9.5.1 Market Size and Forecast
- 9.5.2 Demand Drivers
- 9.5.3 Regional Regulatory Overview
- 9.5.4 Competitive Intensity

10. Key Countries Analysis

10.1 United States
- 10.1.1 Market Size
- 10.1.2 Epidemiology
- 10.1.3 Regulatory Framework
- 10.1.4 Reimbursement Scenario
- 10.1.5 Key Companies and Products Presence
10.2 Canada
10.3 Germany
10.4 United Kingdom
10.5 France
10.6 Italy
10.7 Spain
10.8 China
10.9 Japan
10.10 India
10.11 South Korea
10.12 Australia
10.13 Brazil
10.14 Mexico
10.15 Saudi Arabia
10.16 South Africa

11. Regulatory & Policy Landscape

11.1 Global Regulatory Overview
11.2 United States Regulatory Framework
- 11.2.1 FDA Approval Pathways
- 11.2.2 Controlled Substance Regulations
11.3 Europe Regulatory Framework
- 11.3.1 EMA Regulations
- 11.3.2 Controlled Drug Policies
11.4 Japan Regulatory Framework
- 11.4.1 PMDA Approval Process
11.5 India Regulatory Framework
- 11.5.1 CDSCO Approval Process
11.6 China Regulatory Framework
- 11.6.1 NMPA Approval Process
11.7 Intellectual Property and Patent Landscape
11.8 Pharmacovigilance Requirements

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Competitive Benchmarking
12.3 Product Portfolio Analysis
12.4 Pipeline Competitiveness Assessment
12.5 Strategic Developments
- 12.5.1 Mergers and Acquisitions
- 12.5.2 Licensing Agreements
- 12.5.3 Collaborations and Partnerships
- 12.5.4 Product Launches
12.6 SWOT Analysis

13. Company Profiles

13.1 Takeda Pharmaceutical Company
- 13.1.1 Company Overview
- 13.1.2 Approved ADHD Products: Vyvanse (lisdexamfetamine), Adderall XR (mixed amphetamine salts)
- 13.1.3 Key Indications
- 13.1.4 Pipeline and Strategic Focus
- 13.1.5 Recent Developments
13.2 Eli Lilly and Company
- 13.2.1 Company Overview
- 13.2.2 Approved ADHD Products: Strattera (atomoxetine)
- 13.2.3 Key Indications
- 13.2.4 Pipeline and Strategic Focus
- 13.2.5 Recent Developments
13.3 Supernus Pharmaceuticals
- 13.3.1 Company Overview
- 13.3.2 Approved ADHD Products: Qelbree (viloxazine extended-release)
- 13.3.3 Key Indications
- 13.3.4 Pipeline and Strategic Focus
- 13.3.5 Recent Developments
13.4 Corium LLC
- 13.4.1 Company Overview
- 13.4.2 Approved ADHD Products: Azstarys (serdexmethylphenidate/dexmethylphenidate), Jornay PM (methylphenidate)
- 13.4.3 Key Indications
- 13.4.4 Pipeline and Strategic Focus
- 13.4.5 Recent Developments
13.5 Noven Pharmaceuticals
- 13.5.1 Company Overview
- 13.5.2 Approved ADHD Products: Daytrana (methylphenidate transdermal system)
- 13.5.3 Key Indications
- 13.5.4 Pipeline and Strategic Focus
- 13.5.5 Recent Developments
13.6 Azurity Pharmaceuticals
- 13.6.1 Company Overview
- 13.6.2 Approved ADHD Products: Xelstrym (dextroamphetamine transdermal system)
- 13.6.3 Key Indications
- 13.6.4 Pipeline and Strategic Focus
- 13.6.5 Recent Developments
13.7 Aytu BioPharma
- 13.7.1 Company Overview
- 13.7.2 Approved ADHD Products: Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate)
- 13.7.3 Key Indications
- 13.7.4 Pipeline and Strategic Focus
- 13.7.5 Recent Developments
13.8 Tris Pharma
- 13.8.1 Company Overview
- 13.8.2 Approved ADHD Products: Quillivant XR, QuilliChew ER, Dyanavel XR
- 13.8.3 Key Indications
- 13.8.4 Pipeline and Strategic Focus
- 13.8.5 Recent Developments
13.9 Arbor Pharmaceuticals
- 13.9.1 Company Overview
- 13.9.2 Approved ADHD Products: Evekeo, Evekeo ODT
- 13.9.3 Key Indications
- 13.9.4 Pipeline and Strategic Focus
- 13.9.5 Recent Developments
13.10 Zevra Therapeutics
- 13.10.1 Company Overview
- 13.10.2 ADHD Product and Licensing Portfolio
- 13.10.3 Key Indications
- 13.10.4 Pipeline and Strategic Focus
- 13.10.5 Recent Developments

14. Future Outlook

14.1 Future Market Trends
14.2 Emerging Technologies
14.3 Novel Mechanisms of Action
14.4 Opportunities in Adult ADHD
14.5 Future Competitive Scenario
14.6 Long-Term Market Forecast

15. Methodology

15.1 Research Objectives
15.2 Research Design
15.3 Primary Research Methodology
15.4 Secondary Research Methodology
15.5 Data Validation and Triangulation
15.6 Forecasting Methodology
15.7 Assumptions and Limitations
15.8 Abbreviations and Definitions

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

全球注意力不足/過動症 (ADHD) 治療研發管線分析 - 2026 年（第二季洞察與臨床試驗）

全球注意力不足過動症（ADHD）流行病學分析與預測 - 2026年

注意力不足/過動症（ADHD）全球臨床試驗現況：趨勢與分析（2026版）

全球注意力不足/過動症（ADHD）病例分析與預測：2026-2035年

全球注意力不足過動症（ADHD）市場：競爭分析（2026 年）

注意力不足過動症（ADHD）全球藥物定價和報銷分析（2026-2035 年）

注意力不足過動症（ADHD）市場：策略洞察與預測（2026-2035）

注意力不足過動症 (ADHD) 市場：2026-2032 年全球市場預測（按藥物類別、治療方法、最終用戶、分銷管道、年齡層、性別和診斷類型分類）

全球注意力不足過動症（ADHD）市場規模、佔有率、趨勢和成長分析報告（2026-2034）

注意力不足過動症 (ADHD) 治療市場：按藥物類型、年齡層、分銷管道和地區分類

▼

FAQ

全球注意力不足過動症（ADHD）新興療法報告：2026年第二季度